Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques.Journal of Lipid Research.  59:2075-2083. 2018
2018 The Apolipoprotein E Mimetic Peptide AEM-2 Attenuates Mitochondrial Injury And Apoptosis In Human THP-1 Macrophages.Current topics in peptide & protein research.  19:15-25. 2018
2017 ApoA-I Mimetic Peptide 4F Reduces Age-Related Lipid Deposition in Murine Bruch's Membrane and Causes Its Structural Remodeling.Current Eye Research.  43:135-146. 2017
2016 Apolipoprotein Mimetic Peptides as Modulators of Lipoprotein Function.Protein and Peptide Letters.  23:1024-1031. 2016
2014 Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A.Innate Immunity.  20:867-880. 2014
2014 Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.Journal of Lipid Research.  55:2007-2021. 2014
2013 Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in rats.Biochemical and Biophysical Research Communications.  436:705-710. 2013
2013 Recent progress in the development of apoA-I and apoE mimetic therapiesFuture Lipidology.  8:265-268. 2013
2013 Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice.Atherosclerosis.  227:58-64. 2013
2013 In vivo and in vitro effects of an apolipoprotein e mimetic peptide on amyloid-β pathology.Journal of Alzheimer's Disease.  36:335-347. 2013
2013 Quercetin prevents left ventricular hypertrophy in the Apo E knockout mouse.Redox Biology.  1:381-386. 2013
2012 Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.Atherosclerosis.  224:326-331. 2012
2012 Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides.Journal of Lipid Research.  53:849-858. 2012
2011 Apolipoprotein E mimetics and cholesterol-lowering properties.American Journal of Cardiovascular Drugs.  11:371-381. 2011
2010 Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice.Journal of Lipid Research.  51:3491-3499. 2010
2010 Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects.Atherosclerosis.  213:449-457. 2010
2010 Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2).Atherosclerosis.  208:134-141. 2010
2010 ApoE mimetic peptide reduces plasma lipid hydroperoxide content with a concomitant increase in HDL paraoxonase activity.Advances in Experimental Medicine and Biology.  660:1-4. 2010
2009 Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease.Neurobiology of Disease.  34:525-534. 2009
2009 Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).Vascular Disease Prevention.  6:122-130. 2009
2008 HDL therapy for cardiovascular diseases: the road to HDL mimetics.Current Atherosclerosis Reports.  10:405-412. 2008
2007 Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides.Journal of Lipid Research.  48:1915-1923. 2007
2007 ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers.Journal of Biological Chemistry.  282:1980-1988. 2007
2006 Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins.Current Pharmaceutical Biotechnology.  7:235-240. 2006
2006 Potential clinical utility of high-density lipoprotein-mimetic peptides.Current Opinion in Lipidology.  17:440-444. 2006
2006 Synthetic peptides: managing lipid disorders.Current Opinion in Lipidology.  17:233-237. 2006
2006 Oral amphipathic peptides as therapeutic agents.Expert Opinion on Investigational Drugs.  15:13-21. 2006
2005 An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.Arteriosclerosis, Thrombosis, and Vascular Biology.  25:1932-1937. 2005
2005 Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide.Circulation Research.  97:236-243. 2005
2005 Apolipoprotein A-I mimetic peptides.Arteriosclerosis, Thrombosis, and Vascular Biology.  25:1325-1331. 2005
2005 D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice.Arteriosclerosis, Thrombosis, and Vascular Biology.  25:1426-1432. 2005
2005 Apolipoprotein E mimetic Peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits.Circulation.  111:3112-3118. 2005
2004 Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.Current Opinion in Lipidology.  15:645-649. 2004
2004 Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.Circulation.  109:3215-3220. 2004
2004 Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity.Journal of Biological Chemistry.  279:26509-26517. 2004
2003 Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease.American Journal of Pathology.  163:2155-2164. 2003
2003 Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.Current Opinion in Investigational Drugs.  4:1100-1104. 2003
2003 Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice.Atherosclerosis.  168:229-237. 2003
2002 Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide.Circulation.  106:1127-1132. 2002
2002 Sustained-delivery of an apolipoprotein E-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels.Journal of Controlled Release.  79:207-218. 2002
2002 Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.Circulation.  105:290-292. 2002
2001 Toward the design of peptide mimics of antiatherogenic apolipoproteins A-I and ECurrent Science.  81:53-65. 2001
2001 Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide.Journal of Lipid Research.  42:1096-1104. 2001
2001 Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo.Journal of Lipid Research.  42:959-966. 2001
2001 A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis.Journal of Lipid Research.  42:545-552. 2001
2000 A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples.Journal of Lipid Research.  41:1020-1026. 2000
2000 The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts.Biochemistry.  39:213-220. 2000
1997 Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology.Journal of Lipid Research.  38:2353-2364. 1997
1997 The effects of low-density lipoprotein and high-density lipoprotein on blood viscosity correlate with their association with risk of atherosclerosis in humans.Clinical Science.  92:473-479. 1997
1996 Chromatographic methods for quantitation of apolipoprotein A-I.Methods in Enzymology.  263:267-282. 1996
1995 A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol.Arteriosclerosis, Thrombosis, and Vascular Biology.  15:2151-2156. 1995
1995 Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology.Journal of Lipid Research.  36:2291-2302. 1995
1994 apoB-100 has a pentapartite structure composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCATE.Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association.  14:1674-1685. 1994
1994 Quantification of cholesterol in all lipoprotein classes by the VAP-II method.Journal of Lipid Research.  35:159-168. 1994
1994 The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins.Advances in Protein Chemistry.  45:303-369. 1994
1993 Thyroid function and other clinical chemistry parameters in subjects eating iodine-enriched eggs.Food and Chemical Toxicology.  31:247-251. 1993
1993 Cholesterol-lowering diets: Dealing with long-term adherence problemsCardiology Board Review.  10. 1993
1992 Analysis of cholesterol in all lipoprotein classes by single vertical ultracentrifugation of fingerstick blood and controlled-dispersion flow analysis.Clinical Chemistry.  38:1898-1905. 1992
1992 Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties.Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association.  12:886-894. 1992
1992 Plasma lipoproteins in hyperlipidemic subjects eating iodine-enriched eggs.Journal of the American College of Nutrition.  11:294-303. 1992
1992 Saturated fats, cholesterol, and dietary compliance.Archives of Internal Medicine -New Series-.  152:1167-1174. 1992
1992 Saturated Fats, Cholesterol, and Dietary ComplianceArchives of Internal Medicine -New Series-.  152:1167-1174. 1992
1988 Ascites fluid lipoproteins in experimental nephrotic syndrome.BBA - Biochimica et Biophysica Acta.  959:253-261. 1988
1985 Lipoproteins of ascites fluid from nephrotic ratsFederation proceedings.  44:6112. 1985
1984 Catabolism of very low density lipoproteins in experimental nephrosis.Journal of Clinical Investigation.  74:1375-1383. 1984

Research Overview

  • Coronary vascular disease, including heart disease and stroke, is the leading cause of death in the developed world. Numerous studies have shown that high levels of low density lipoprotein (LDL) cholesterol are associated with increased risk for atherosclerotic heart disease, while high levels of high density lipoprotein (HDL) are associated with reduced risk. The major protein component of HDL, apolipoprotein (apo) A-I, is considered to be primarily responsible for the atheroprotective properties of HDL. Apo E associates with chylomicrons, very low density lipoproteins (VLDL), and HDL, and mediates the clearance of triglyceride-rich lipoproteins. Both apo A-I and E have anti-inflammatory properties that contribute to atheroprotective properties. Our group has pioneered the design of peptide mimetics of apolipoproteins that have similar structural motifs as apo A-I and apo E, and has used these mimetic peptides to study the physical properties of apo A-I and apo E. My laboratory has extended these studies into animal models with the intent to use peptide mimetics of apolipoproteins to determine what properties of apo A-I and apo E prevent atherosclerosis and inflammatory processes in vivo. We are now extending these studies into animal models of Alzheimer ’s disease and insulin resistance.
  • Education And Training

    Full Name

  • David Garber
  • Blazerid

  • dgarber